Recent innovations in genome editing reveal transformative potential. Researchers introduced a near-infrared-activated chemically induced CRISPR system enabling precise spatiotemporal control of gene edits. The historic treatment of 'Baby KJ' with a customized gene-editing therapy highlights the manufacturing challenges and future scalability of individualized genomic medicines. Additionally, Nature Biotechnology outlines the ongoing evolution and challenges for customized base editors and prime editors, underscoring the expanding clinical impact.